Rapid Clinical Recovery from Critical COVID-19 Pneumonia with Vasoactive Intestinal Peptide Treatment

INTRODUCTION: RLF-100 (Aviptadil), a synthetic form of human Vasoactive Intestinal Peptide (VIP), is in clinical trials for treatment of critical COVID-19 pneumonia with respiratory failure. VIP was shown to protect the lung against a broad array of injuries by binding to the VPAC(1) receptor of alv...

Descripción completa

Detalles Bibliográficos
Autores principales: Beshay, S., Youssef, J.G., Zahiruddin, F., Al-Saadi, M., Yau, S., Goodarzi, A., Huang, H., Javitt, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2021
Materias:
(1268)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979412/
http://dx.doi.org/10.1016/j.healun.2021.01.2036

Ejemplares similares

Ejemplares similares